U.S. FDA Authorized The First And Only Protein-Based Non-MRNA Updated Covid-19 Vaccine For Use In People Aged 12 Years And Older
Portfolio Pulse from Benzinga Newsdesk
The U.S. FDA has authorized the first and only protein-based non-mRNA updated Covid-19 vaccine for use in people aged 12 years and older. The vaccine is likely produced by Novavax (NVAX).
October 03, 2023 | 6:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novavax's Covid-19 vaccine has been authorized by the U.S. FDA for use in people aged 12 years and older. This is the first and only protein-based non-mRNA vaccine to receive such authorization.
The FDA's authorization of Novavax's Covid-19 vaccine is a significant milestone for the company. It is the first and only protein-based non-mRNA vaccine to receive such authorization, which could lead to increased demand for the vaccine. This could potentially boost Novavax's revenues and positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100